advertisement
Odani-Kawabata N 9
Showing records 1 to 9 | Display all abstracts from Odani-Kawabata N117535 Omidenepag Isopropyl 0.002% versus Latanoprost 0.005% in Open-Angle Glaucoma/Ocular Hypertension: The Randomized Phase III PEONY Trial
Wang TH
Clinical Ophthalmology 2024; 18: 2093-2106
117008 Omidenepag Isopropyl Versus Timolol in Patients With Glaucoma or Ocular Hypertension: Two Randomized Phase 3 Trials (SPECTRUM 4 and 3)
Bacharach J; Brubaker JW
American Journal of Ophthalmology 2024; 263: 23-34
117535 Omidenepag Isopropyl 0.002% versus Latanoprost 0.005% in Open-Angle Glaucoma/Ocular Hypertension: The Randomized Phase III PEONY Trial
Aung T
Clinical Ophthalmology 2024; 18: 2093-2106
117008 Omidenepag Isopropyl Versus Timolol in Patients With Glaucoma or Ocular Hypertension: Two Randomized Phase 3 Trials (SPECTRUM 4 and 3)
Evans DG
American Journal of Ophthalmology 2024; 263: 23-34
117535 Omidenepag Isopropyl 0.002% versus Latanoprost 0.005% in Open-Angle Glaucoma/Ocular Hypertension: The Randomized Phase III PEONY Trial
Lu DW; George R
Clinical Ophthalmology 2024; 18: 2093-2106
117008 Omidenepag Isopropyl Versus Timolol in Patients With Glaucoma or Ocular Hypertension: Two Randomized Phase 3 Trials (SPECTRUM 4 and 3)
Lu F; Odani-Kawabata N
American Journal of Ophthalmology 2024; 263: 23-34
117535 Omidenepag Isopropyl 0.002% versus Latanoprost 0.005% in Open-Angle Glaucoma/Ocular Hypertension: The Randomized Phase III PEONY Trial
Senthil S; Lu F
Clinical Ophthalmology 2024; 18: 2093-2106
117008 Omidenepag Isopropyl Versus Timolol in Patients With Glaucoma or Ocular Hypertension: Two Randomized Phase 3 Trials (SPECTRUM 4 and 3)
Yamabe T; Wirta DL
American Journal of Ophthalmology 2024; 263: 23-34
117535 Omidenepag Isopropyl 0.002% versus Latanoprost 0.005% in Open-Angle Glaucoma/Ocular Hypertension: The Randomized Phase III PEONY Trial
Odani-Kawabata N; Park KH
Clinical Ophthalmology 2024; 18: 2093-2106
